What to add to an anti-PD-(L)1 backbone when PD-1 blockade alone is not enough: inhibitory checkpoints beyond PD-1 such as LAG-3, TIGIT and TGF-beta, co-stimulatory agonists, and targeted agents paired with immunotherapy to overcome acquired resistance — and whether a second agent improves response or only adds toxicity.
In the single-center, nonrandomized, open-label phase II NEST trial (24 patients, 26 tumors), neoadjuvant botensilimab plus balstilimab before colon cancer resection produced a major pathologic response in 41% (9/22; 95% CI, 21%–64%) of mismatch repair-proficient tumors and in 4 of 4 mismatch repair-deficient tumors, with no delay to planned surgery.
In an open-label, single-center, single-arm phase II trial at UCSF, 42 previously treated patients with advanced biliary cancer received pembrolizumab plus GM-CSF. The confirmed objective response rate was 12% (5 of 42; 95% CI: 0.04, 0.26), below the prespecified 20% threshold for meaningful efficacy. Median progression-free survival was 2.1 months (95% CI: 1.8, 4.2) and median overall survival was 13.1 months (95% CI: 8.1, 19.1).
PEMDA-HN was a multicenter, randomized, open-label phase 2 study at 22 centers in 3 countries comparing danvatirsen plus pembrolizumab with pembrolizumab alone as first-line treatment in PD-L1-positive (combined positive score ≥1) recurrent or metastatic head and neck squamous cell carcinoma. Of 69 patients randomized 2:1, 66 were treated (45 vs 21). The confirmed objective response rate, the primary endpoint, was 15.6% (7/45) with the combination vs 14.3% (3/21) with pembrolizumab alone (risk difference 1.3; 90% CI −14.1 to 16.7; Fisher's exact P = 1.0000).
In the randomized, open-label COMMIT trial (NRG-GI004/SWOG-S1610), 82 patients with previously untreated dMMR/MSI-H metastatic colorectal cancer were randomized 1:1 to mFOLFOX6/bevacizumab/atezolizumab (FFX/bev/atezo) or atezolizumab alone. At the November 6, 2025 cutoff (median follow-up 46 months), progression-free survival favored the combination: HR=0.42 (95% CI, 0.22–0.80; P=0.0068), with median PFS of 24.5 versus 5.3 months.
VERSATILE-002 was a phase 2, open-label, multicenter, nonrandomized trial of the HPV16 E6/E7 peptide vaccine PDS0101 combined with pembrolizumab in HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. 87 patients were treated in two separately analyzed cohorts: immune checkpoint inhibitor (ICI)-naive and ICI-resistant.
A randomized phase II trial testing whether the CD27 costimulatory agonist varlilumab, combined with atezolizumab and the MEK inhibitor cobimetinib, could rescue checkpoint-inhibitor activity in previously treated, unresectable biliary tract cancer closed early for futility after a preplanned interim analysis.
The phase 3 COMBI-I trial's final long-term follow-up analysis reports a numerically longer overall survival with the anti-PD-1 antibody spartalizumab added to dabrafenib and trametinib, versus dabrafenib and trametinib alone, in 532 patients with BRAF V600-mutant advanced melanoma.
An open-label phase 1b expansion cohort within a larger basket study tested Fc-enhanced anti-CTLA-4 antibody botensilimab plus anti-PD-1 antibody balstilimab in 123 patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, most of whom were heavily pretreated.
A first-in-human, open-label, single-arm phase I/II trial tested whether an intratumoral CD40 agonist (sotigalimab) added to systemic pembrolizumab could turn immunologically "cold" tumors "hot" in patients with immune-checkpoint-blockade-naive metastatic melanoma.
A global, randomized, double-blind, placebo-controlled phase 3 trial (SKYSCRAPER-01) tested whether adding the anti-TIGIT antibody tiragolumab to atezolizumab would improve outcomes over atezolizumab alone in previously untreated, PD-L1-high non-small cell lung cancer (NSCLC).
A single-center, investigator-initiated Phase Ib/II trial (NCI protocol 18-C-0110, NCT03554473) tested bintrafusp alfa — a bifunctional PD-L1/TGF-β fusion protein — alone or with chemotherapy in 37 patients with relapsed small cell lung cancer treated between 2019 and 2022.
A Phase 2 arm of the adaptive I-SPY2 platform trial (78 patients treated 2020-2021, compared against 350 historical controls) tested adding cemiplimab (anti-PD-1) and fianlimab (anti-LAG-3) to neoadjuvant chemotherapy in high-risk, stage II-III, ERBB2 (HER2)-negative breast cancer.
Randomized (2:1), open-label, international phase II trial of ceralasertib (an oral ATR inhibitor) plus durvalumab versus ceralasertib monotherapy in 151 patients with advanced melanoma that had progressed on prior anti-PD-(L)1 therapy
Open-label, multicenter phase 1 trial (Adult Brain Tumor Consortium, ABTC 1501) of the anti-LAG-3 antibody relatlimab, alone or combined with the anti-PD-1 antibody nivolumab, in 46 patients with first-time recurrent glioblastoma (GBM)
Randomised, double-blind, phase 3 study of 1,402 patients with surgically resected stage IIB–IV cutaneous melanoma across 205 global sites